Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 5/20 | 0.38 |
| ▸ | BCHE | P06276 | 4/20 | 0.38 |
| ▸ | PPARG | P37231 | 6/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CTSD | P07339 | 1/20 | 0.37 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.36 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5720767 | 0.79 | TXNRD1 (0.39) | BACE1BCHEPPARGEPHX2KDM4E | |
| SCHEMBL3351983 | 0.71 | EPHX2 (0.44) | BACE1BCHEPPARGEPHX2KDM4E | |
| SCHEMBL6889938 | 0.71 | EPHX2 (0.44) | BACE1BCHEPPARGEPHX2KDM4E | |
| SCHEMBL5444963 | 0.70 | BACE1 (0.53) | BACE1BCHEPPARGEPHX2CTSD | |
| SCHEMBL5444966 | 0.70 | BACE1 (0.53) | BACE1BCHEPPARGEPHX2CTSD | |
| SCHEMBL1938155 | 0.69 | BACE1 (0.60) | BACE1BCHECTSD | |
| SCHEMBL1938153 | 0.69 | BACE1 (0.60) | BACE1BCHECTSD | |
| SCHEMBL8580373 | 0.67 | BCHE (0.52) | BACE1BCHE | |
| SCHEMBL24517077 | 0.64 | MAOB (0.46) | KDM4EALDH1A1TDP1MAOB | |
| SCHEMBL5549274 | 0.64 | MAOB (0.46) | KDM4EALDH1A1TXNRD1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060211740-A1 | Novel compounds | GLAXO GROUP LIMITED | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211740-A1 | Novel compounds | BACE2, BACE1, PSEN2 | BACE1 2/4885BCHE 24/4885PPARG 4627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.